Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension

An accumulating body of evidence incriminates Rho kinase (ROCK) in the pathogenesis of pulmonary hypertension (PH). The therapeutic efficacy of azaindole-1, a novel highly selective and orally active ROCK inhibitor, has not yet been investigated in PH. This study aimed to investigate the effects of azaindole-1 on 1) acute hypoxic pulmonary vasoconstriction (HPV), 2) proliferation of pulmonary arterial smooth muscle cells (PASMCs) and 3) animal models of PH. Azaindole-1 significantly inhibited HPV in isolated, ventilated and buffer-perfused murine lungs and proliferation of primary rat PASMCs in vitro. Azaindole-1 was administered orally from 21 to 35 days after monocrotaline (MCT) injection in rats and hypoxic exposure in mice. Azaindole-1 (10 and 30 mg per kg body weight per day in rats and mice, respectively) significantly improved haemodynamics and right ventricular hypertrophy. Moreover, the medial wall thickness and muscularisation of peripheral pulmonary arteries were ameliorated. Azaindole-1 treatment resulted in a decreased immunoreactivity for phospho-myosin phosphatase target subunit 1 and proliferating cell nuclear antigen in pulmonary vessels of MCT-injected rats, suggesting an impaired ROCK activity and reduced proliferating cells. Azaindole-1 provided therapeutic benefit in experimental PH, and this may be attributable to its potent vasorelaxant and antiproliferative effects. Azaindole-1 may offer a useful approach for treatment of PH.

[1]  B. Dahal,et al.  Role of epidermal growth factor inhibition in experimental pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[2]  H. Fujita,et al.  Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[3]  B. Dahal,et al.  The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[4]  Yingling Liu,et al.  Serotonin induces Rho/ROCK‐dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  N. Weissmann,et al.  Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[6]  M. Humbert,et al.  Future perspectives for the treatment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[7]  W. Seeger,et al.  The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. , 2009, American journal of respiratory cell and molecular biology.

[8]  X. Zheng,et al.  ROCK Isoform Regulation of Myosin Phosphatase and Contractility in Vascular Smooth Muscle Cells , 2009, Circulation research.

[9]  M. Humbert,et al.  RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. , 2009, American journal of respiratory and critical care medicine.

[10]  W. Xia,et al.  Acute Inhibition of Rho-Kinase Attenuates Pulmonary Hypertension in Patients with Congenital Heart Disease , 2009, Pediatric Cardiology.

[11]  J. Stasch,et al.  Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors , 2008, ChemMedChem.

[12]  M. Oka,et al.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension , 2008, British journal of pharmacology.

[13]  M. Humbert,et al.  Review: Therapeutic advances in pulmonary arterial hypertension , 2008, Therapeutic advances in respiratory disease.

[14]  L. Walker,et al.  Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[15]  P. McNamara,et al.  Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[16]  田原 俊介.  Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats , 2008 .

[17]  A. Zaiman,et al.  PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[18]  M. Oka,et al.  Endothelin-1 and Serotonin are Involved in Activation of RhoA/Rho Kinase Signaling in the Chronically Hypoxic Hypertensive Rat Pulmonary Circulation , 2007, Journal of cardiovascular pharmacology.

[19]  J. Stasch,et al.  Cardiovascular effects of a novel potent and highly selective azaindole‐based inhibitor of Rho‐kinase , 2007, British journal of pharmacology.

[20]  H. Shimokawa,et al.  Effects of Combined Therapy With a Rho-Kinase Inhibitor and Prostacyclin on Monocrotaline-Induced Pulmonary Hypertension in Rats , 2007, Journal of cardiovascular pharmacology.

[21]  R. Johns,et al.  Regression of chronic hypoxic pulmonary hypertension by simvastatin. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[22]  W. Seeger,et al.  Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy , 2007, Circulation.

[23]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[24]  H. Shimokawa,et al.  Acute Vasodilator Effect of Fasudil, a Rho-kinase Inhibitor, in Monocrotaline-Induced Pulmonary Hypertension in Rats , 2007, Journal of cardiovascular pharmacology.

[25]  Ruopeng Sun,et al.  Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. , 2007, Pharmacological research.

[26]  K. Kaibuchi,et al.  Long-Term Inhibition of Rho-kinase Ameliorates Hypoxia-Induced Pulmonary Hypertension in Mice , 2006, Journal of cardiovascular pharmacology.

[27]  Hiroaki Shimokawa,et al.  ROCK Controls Matrix Synthesis in Vascular Smooth Muscle Cells: Coupling Vasoconstriction to Vascular Remodeling , 2006, Circulation research.

[28]  K. Morris,et al.  Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. , 2006, Journal of applied physiology.

[29]  P. Pacaud,et al.  Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.

[30]  T. Nakano,et al.  Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[31]  H. Hidaka,et al.  Development of specific Rho-kinase inhibitors and their clinical application. , 2005, Biochimica et biophysica acta.

[32]  P. Pacaud,et al.  Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension , 2005, British journal of pharmacology.

[33]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[34]  P. McLoughlin,et al.  Inhibition of Rho-Kinase Attenuates Hypoxia-Induced Angiogenesis in the Pulmonary Circulation , 2005, Circulation research.

[35]  H. Shimokawa,et al.  Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.

[36]  A. Takeshita,et al.  Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension , 2005, Heart.

[37]  K. Morris,et al.  Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[38]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[39]  K. Kaibuchi,et al.  Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.

[40]  W. Seeger,et al.  Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. , 2004, American journal of respiratory and critical care medicine.

[41]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[42]  A. Takeshita,et al.  Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  H. Hidaka,et al.  H-series protein kinase inhibitors and potential clinical applications. , 1999, Pharmacology & therapeutics.

[44]  H. Nagumo,et al.  HA1077, a protein kinase inhibitor, inhibits calponin phosphorylation on Ser175 in porcine coronary artery. , 1998, European journal of pharmacology.

[45]  Yasuharu Sasaki,et al.  A Protein Kinase Inhibitor, Fasudil (AT‐877): A Novel Approach to Signal Transduction Therapy , 1998 .

[46]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[47]  K. Nakao,et al.  ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.

[48]  T. Yamamoto,et al.  Rho‐associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. , 1996, The EMBO journal.

[49]  L. Lim,et al.  A Novel Serine/Threonine Kinase Binding the Ras-related RhoA GTPase Which Translocates the Kinase to Peripheral Membranes (*) , 1995, The Journal of Biological Chemistry.